Oruka Therapeutics Inc., a clinical-stage biotechnology company, announced its financial results for the first quarter of 2025, highlighting a strong cash position and providing updates on its research programs. As of March 31, 2025, Oruka reported cash, cash equivalents, and marketable securities totaling $373.0 million, sufficient to fund operations through 2027. The company recorded a net loss of $21.0 million for the quarter, an increase from a net loss of $7.1 million during the period from February 6, 2024, to March 31, 2024. This loss includes non-cash stock-based compensation of $4.9 million, up from $0.1 million in the same period of the previous year. Other income for the first quarter of 2025 was $4.1 million, primarily from interest earned on investments in marketable securities. Operational updates include the completion of Phase 1 trial dosing for ORKA-001, with data expected in the third quarter of 2025 and the initiation of Phase 2a trials in the second half of 2025. ORKA-002's Phase 1 initiation has been accelerated to the second quarter of 2025, with initial pharmacokinetic data anticipated by year-end 2025. The company also continues to develop ORKA-003 through preclinical stages but will not disclose further details in the first half of 2025 due to competitive considerations.